Mutations in the X-linked gene MECP2 are associated with a severe neurodevelopmental disorder, Rett syndrome (RTT), primarily in girls. It had been suspected that mutations in Methyl-CpGbinding protein 2 (MECP2) led to embryonic lethality in males, however such males have been reported. To enhance understanding of the phenotypic spectrum present in these individuals, we identified 30 males with MECP2 mutations in the RTT Natural History Study databases. A wide phenotypic spectrum was observed, ranging from severe neonatal encephalopathy to cognitive impairment. Two males with a somatic mutation in MECP2 had classic RTT. Of the remaining 28 subjects, 16 had RTT-causing MECP2 mutations, 9 with mutations that are not seen in females with RTT but are likely pathogenic, and 3 with uncertain variants. Two subjects with RTT-causing mutations were previously diagnosed as having atypical RTT; however, careful review of the clinical history determined that an additional 12/28 subjects met criteria for atypical RTT, but with more severe clinical presentation and course, and less distinctive RTT features, than females with RTT, leading to the designation of a new diagnostic entity, male RTT encephalopathy. Increased awareness of the clinical spectrum and widespread comprehensive genomic testing in boys with neurodevelopmental problems will lead to improved identification.
| INTRODUCTION

Rett syndrome (RTT) is a neurodevelopmental disorder occurring almost exclusively in females and results primarily from mutations in
Methyl-CpG-binding protein 2 (MECP2), the gene that encodes the transcriptional regulator MeCP2 (Amir et al., 1999; Hagberg, Aicardi, Dias, & Ramos, 1983; Rett, 1966) . Two diagnostic entities have been identified based on the number of main and supportive diagnostic criteria (Neul et al., 2010) : typical or classic RTT and atypical or variant RTT. RTT has been identified in boys who typically fall into two categories, those with 47XXY (Klinefelter syndrome; Schwartzman, Bernardino, Nishimura, Gomes, & Zatz, 2001; Vorsanova et al., 2001) or those with somatic mosaicism (Clayton-Smith, Watson, Ramsden, & Black, 2000) . Rarely, atypical RTT has been noted in XY nonmosaic males with MECP2 mutations associated with milder disease in females with RTT (Dayer et al., 2007; Neul et al., 2014) . Despite the reports of males with MECP2 mutations surviving, some recent publications continue to present a misconception that males with MECP2 mutations did not survive pregnancy or had an early-onset severe encephalopathy that resulted in death at a very young age (Chen et al., 2017) . Initial attempts to develop a mouse model lacking Mecp2 failed due to intrauterine demise (Tate, Skarnes, & Bird, 1996) . Subsequently, the same laboratory generated a mouse Mecp2 null mouse using modified methodology, demonstrating that loss of MeCP2 function does not lead to embryonic lethality (Guy, Hendrich, Holmes, Martin, & Bird, 2001) . Thereafter, several reports of affected human males emerged such that experienced clinicians recognize a spectrum of clinical involvement in males with MECP2 mutations. These include mutations seen in females with RTT (Augenstein, Lane, Horton, Schanen, & Percy, 2009; Bianciardi et al., 2016; Kankirawatana et al., 2006; Schule, Armstrong, Vogel, Oviedo, & Francke, 2008; Villard, 2007) , as well as mutations which appear to produce abnormal neurodevelopment only in males Dotti et al., 2002; Gomot et al., 2003; Klauck et al., 2002; Lambert et al., 2016; Moog et al., 2003; Orrico et al., 2000; Winnepenninckx, Errijgers, HayezDelatte, Reyniers, & Frank Kooy, 2002) . Nonetheless, the misperception among those not familiar with RTT that males with MECP2 mutations do not survive pregnancy or die within the first year of life unless afforded ventilatory support has been repeated in the published literature on animal models (Chen et al., 2017) . Further, the suggestion that RTT occurs in males despite not meeting the established consensus criteria, or even having a duplication in MECP2, is still evident (Reichow, George-Puskar, Lutz, Smith, & Volkmar, 2015) .
The occurrence of RTT predominantly in females is principally the result of de novo mutations, especially deamination of methylated cytosines, occurring in rapidly dividing germinal cells, namely sperm (Cuddapah et al., 2014; Girard et al., 2001; Thomas, 1996; Zhu et al., 2010) . Such mutations cannot be transmitted to a male, explaining in part the lower frequency of affected males. Occasionally, RTT results from mutations in transmitting females who themselves do not fulfill the criteria for RTT, either having mild cognitive impairment or learning disability or being phenotypically normal, all related to unbalanced or skewed X chromosome inactivation (XCI; Augenstein et al., 2009; Schanen, 2001; Schanen & Francke, 1998) . In other instances, the mutation may be a de novo event in the ovum. 
| Diagnosis
In RTT5201, a RNHS neurologist or geneticist (DGG, SAS, WEK, JLN, and AKP) with extensive clinical experience in RTT utilized the established criteria for diagnosis of RTT or other related phenotypes. In RTT5211, a neurologist or geneticist (TAB, JLN, SAS, EDM, or AKP) characterized nine males including the one male carried forward from RTT5201. All participants in the RNHS were required either to meet clinical criteria for RTT and/or to have a mutation in MECP2. The clinical diagnosis was determined from the information present within the RNHS database, and cases were classified as RTT (classic or atypical) if they met consensus criteria, neonatal encephalopathy if they showed impairment from birth, progressive encephalopathy if the presentation was delayed and worsening, or cognitive impairment if they did not show progressive worsening over the course of the study (Table 1) .
| Genetic testing and mutation classification
Genetic testing consisted of Sanger sequencing of all four exons, and evaluation for large rearrangements if no sequence variants discovered. In 24 of the 30 cases, genetic information from the mother or sister of the affected individual was also available allowing for determination of inheritance pattern (Table 1) . Neul et al., 2008) , and survival (Kirby et al., 2010; Tarquinio et al., 2015) . Increasing overall scores on both the CSS and the MBA represent increasing severity.
| HUMAN STUDIES APPROVAL
Each site obtained and maintained Institutional Review Board (ethics) approval for the performance of these studies. The study clinicians verified all data at time of interview and examination. Parents or authorized caregivers provided approval for study conduct and publication of results prior to entry into the study. We registered these observational studies in ClinicalTrials.gov: NCT00299312 for RTT5201 and NCT02738281 for RTT5211.
| RESULTS
The 30 males with MECP2 variants identified in the RNHS vary in age at diagnosis from 0.6 to 20.4 years ( Table 1 ). The variants span the entire gene, with 18 RTT-causing mutations, nine pathogenic or likely pathogenic but not RTT-causing mutations, and three variants that upon further evaluation are likely benign (Table 1) . Table 2 presents the bioinformatics evaluation of the likely pathogenic group.
| Classification of genetic variants in MECP2
The identified genetic changes were first classified as being clearly RTT-causing (n = 18) or not (n = 12; Table 1 ). Determination that a mutation was RTT-causing was based on whether the genetic change had previously been identified in females with RTT (Cases 1, 2, 4, 5, 6, 8, 9, 10, 11, 14, 15, 16, 17, and 18) The remaining MECP2 sequence variants were evaluated in silico (Table 2 ). Eight of the cases had MECP2 mutations in which the majority of the prediction programs indicated deleterious effects of the variant and were considered "Likely Pathogenic" (Cases 19, 20, 22, 23, 24, 25, 26, and 27) . Case 21 had a p.A140V mutation, which has been reported multiple times in boys with intellectual disability, neuropsychiatric, and movement abnormalities (Cohen et al., 2002) and is considered pathogenic although not associated with RTT.
Three subjects had sequence variation in MECP2 that do not clearly disrupt function ( ). This variant was found in both the mother and grandmother and associated with a random (70:30) XCI pattern in the mother. The grandmother's XCI results were uninformative. The grandmother appears normal, but the mother has at least mild cognitive impairments. From this analysis, it is unclear whether any of these variants are causative, therefore we categorize them as "Uncertain".
| Individuals characterized as RTT
Two subjects were classified as classic RTT and were shown to have somatic mutations, leading to a cellular mosaic pattern of mutation.
These individuals did not have the major exclusion criteria for classic RTT (poor early development, Table 3 ), and met all four main inclusion criteria (loss of hand skills, loss of spoken communication, hand stereotypies, and abnormal gait, Table 3 ). As classic RTT has been identified in males with somatic mutations in MECP2 before (Clayton-Smith et al., 2000) , this is not unexpected.
Two additional subjects (Cases 13, 14), both with RTT-causing MECP2 mutations, were classified as having atypical RTT (Table 1) .
Both subjects had normal initial development followed by regression (Table 2) , and clearly met three of the four main criteria (Table 3 ) and more than five of eleven supportive criteria ( 
| Subjects with RTT-causing mutations in MECP2
Sixteen subjects had germline (nonmosaic) MECP2 mutations either found in or similar to those found in females with RTT, designated RTT-causing (Table 1) . Inheritance from the mother occurred in eight, five were de novo, and in three cases parental mutational testing was not performed. Within this group, four were classified as neonatal encephalopathy, five with progressive encephalopathy, two atypical RTT, and five with cognitive impairment.
Eleven subjects in this group showed markedly abnormal early development and nine had a clear history of regression (Table 3) .
Seven had a clear history of lost hand skills, which ranged from the loss of pincer grasp to the loss of reaching for objects. Notably, regression of hand skills was observed very late in two subjects (cases 16 and 17), both of whom have the same carboxy-terminal truncating mutation inherited from their mothers. These subjects are related as uncle and nephew, and the younger individual has a sister with classic RTT, as previously reported (Augenstein et al., 2009) . Of the nine who did not have any clear history of loss of hand skills, marked variation in the maximal hand skills gained was noted, ranging from no notable hand skills attained to pincer grasp. Only two of the sixteen gained and retained pincer grasp, and 5/16 either had no hand skills or lost all hand skills.
In general, acquisition of spoken language was markedly impaired in the 16 subjects with RTT-causing mutations (Table 3) , with three attaining no vocalizations at all, eight gaining vocalizations, three gaining babbling, and one achieving words. Six showed loss of spoken language, with five ultimately having no utterances at all and only one regaining babbling. Eventually, all vocalization was completely absent in eight, seven with only vocalizations, and one able to babble.
Clear, persistent hand stereotypies were found in seven subjects and one had no hand stereotypies at all. Eight had transient stereotypies, with face/eye/nose rubbing in six. Only one of the 16 subjects attained and maintained independent normal gait (Case 3), whereas nine never gained any gait skills. Of the remaining six, four lost all acquired gait, and two retained independent dyspraxic gait. Thus, the majority of subjects in this group (13/16) eventually had no gait skills at all. Previous work exploring the genotype-phenotype relationship in females with RTT revealed increased severity in early truncating mutations compared to late truncating mutations, and the presence of point mutations such as p.R133C conferring less severity (Cuddapah et al., 2014; Neul et al., 2008) . Within this cohort of males with RTTcausing mutations, we did not observe decreased severity in boys with p.R133C mutations (Cases 5 and 6) compared to other mutations. However, observable differences are noted when comparing all early mutations (before codon 271) and late mutations (Figure 1) . We chose codon 271 as the dividing point between early and late mutations because clear phenotypic differences exist in females with RTT (Cuddapah et al., 2014) and in mouse models (Baker et al., 2013) between those individuals with truncations before codon 270 and after codon 270. In general, males with early RTT mutations had a higher CSS score compared to those with late RTT mutations, with the exception of one outlier in each group (Case 3, an exon 1 mutation, and case 18, a very late truncating mutation). Furthermore, in the early mutation group, 8/9 were classified as either neonatal or progressive encephalopathy, whereas only 1/7 had progressive encephalopathy in the late mutation group. A greater percentage of subjects with early mutations had periodic breathing, bruxism, growth failure, and microcephaly, whereas a greater percentage of subjects with late mutations had sleep issues and screaming (Table 5 ).
| Subjects with non RTT-causing but likely pathogenic mutations in MECP2
Nine subject had mutations in MECP2 that have not been seen in (Table 2) . Three individuals had identified inherited mutations, two clearly identified in mother and one presumably from mother because the same mutation was identified in a sister (Table 1) . In this instance, testing the mother was not possible due to her inability to provide informed consent because of intellectual disability and neuropsychiatric features. Those mothers who tested positive were cognitively impaired according to previously obtained IQ testing. Three mutations were de novo and three parents were not tested.
Six of the nine in this group had normal initial development, and five had clear evidence of regression (Table 2) . Two did not gain any hand skills, two achieved finger feeding, and five attained pincer grasp.
Four had loss of hand skills, with one (Case 23) regaining the lost skill (reaching) and continuing to gain new skills (pincer). Three of the nine ultimately were able to maintain a pincer. Five subjects had 2/4 main criteria, but one did not have a history of regression and thus is excluded from the possibility of having a diagnosis of RTT.
Only one subject in this group lost vocalizations (Case 25). Of the eight with no history of language loss, three did not gain any spoken language at all and had no utterances, two only gained vocalizations, one had multiple words, and two could speak in sentences. Thus, the range of language abilities in this group is very wide. Gait was also highly variable in this group, with five not attaining any gait, one able Mosaic RTT (n = 2)
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Three subjects had no evidence of hand stereotypies. One showed persistent hand clapping and finger rubbing, and five had Nearly all subjects in this group (8/9) had bruxism, sleep issues, and poor pain response (Tables 4 and 5 ). The majority also had abnormal muscle tone. Periodic breathing, scoliosis, and small hands or feet were only present in a third of the cases, and microcephaly in just over a half. Screaming was present in two subjects, and only one person had seizures. Seven of the nine had more than 5/11 supportive criteria.
| Subjects with uncertain variants in MECP2
The three individuals with uncertain genetic variants in MECP2 had abnormal initial development, and only one had a clear history of One did not gain any spoken language, one only gained vocalization, and one lost words. Only one had persistent hand stereotypies, whereas the other two had nonpersistent transient stereotypies.
Finally, none of these individuals gained any ability to walk.
All the subjects in this group had bruxism, small hands or feet, and poor pain response (Tables 4 and 5 ), but none had periodic breathing, eye pointing or microcephaly. Two had peripheral vasomotor abnormalities and screaming, and only one had seizures. All had 8/11 supportive criteria.
| Strict application of RTT diagnostic criteria leads to definition of new entity: male RTT encephalopathy
Aside from the two cases with somatic mosaic mutations in MECP2
who clearly met all the criteria for classic RTT, only two of the remaining 28 were classified in the NHS database as atypical RTT, with the remainder classified as neonatal encephalopathy, progressive encephalopathy, or cognitive impairment. However, when the clinical criteria were strictly applied to these cases, we determined that 12 additional cases 6, 8, 16, 17, 18; likely pathogenic mutations: Cases 7, 21, 22, 25, 26, 30) had a history of regression, at least two of the four major criteria (Table 3) , and at least 5/11 supportive diagnostic criteria (Table 4) .
The majority (8/12) of these individuals (classified as "male RTT encephalopathy) did not have normal initial development. Nine of the 12 had loss of hand skills and 5 had loss of spoken language. Only two had persistent hand stereotypies, whereas the remaining 10 had transient hand stereotypies. All 12 had abnormal gait, with 9 either not attaining gait or completely losing gait.
The most commonly present supportive criteria present were abnormal muscle tone and poor pain response in 11/12. Growth failure and small hands or feet were present in 8/12, and sleep issues in 7/12. Six individuals had period breathing, bruxism, or screaming, five had scoliosis, and four had peripheral vascular abnormalities. Interestingly, none had eye pointing, a very distinctive feature in typical RTT in females.
| DISCUSSION
Early publications had suggested that mutation in MECP2 leads to , whereas few of these individuals were suspected as having MECP2 mutations. We expect that as whole exome or genome sequencing becomes commonly used to characterize males with neurodevelopmental disorders, it is likely that the identification of MECP2 mutations in these males will increase. A limitation of the present study is that the relatively small number of subjects identified at this time precludes comprehensive description of the entire range of clinical features, prognosis, and incidence.
Increasing genetic identification of males with MECP2 mutations will improve the delineation of this group. Another limitation is a more complete analysis of the behavioral features of these males, especially for males with less severe clinical presentations. Previous work has indicated that males with the p.A140V mutation show significant neuropsychiatric features such as mania and even psychosis. Unfortunately, it was beyond the scope and capabilities of this study to assess neuropsychiatric features in a systematic manner. Future work should evaluate these features in more depth.
A high proportion of males with MECP2 mutations display greater clinical severity than females with RTT. Of the 28 subjects who did not have somatic mutations in MECP2, the majority (17/28) had abnormal initial development, a significant fraction (12/28) had neonatal or progressive encephalopathy, two were ventilator dependent, and nine died (mean age of death: 9.0 years). All of these features are uncommon and more severe than in females with RTT. The overall level of skills attained by these males was also much lower than those in females with RTT (Neul et al., 2014) .
We are now able to begin to identify initial genotype-phenotype relationship in males with MECP2 mutations. The presence of neonatal/progressive encephalopathy is much more common in males with RTT-causing MECP2 mutations (56%), compared to either males with likely pathogenic non RTT-causing MECP2 mutations (33%) or uncertain variants (33%). This relationship is clearer when we split the RTT-causing group into early (89%) and late (11%) MECP2 mutations.
The overall clinical severity, as measured by the CSS, also demonstrated that early MECP2 mutations (both truncating as well as missense mutations) were associated with increased severity.
Identification and characterization of additional subjects is needed to develop a deeper genotype-phenotype correlation.
Previous reports have indicated that very few males with MECP2 mutations and unusual genetic features, such as somatic mutations or sexchromosomal abnormalities such as Klinefelter syndrome (XXY), display the full clinical features required to make the diagnosis of RTT. Two of the boys in this report had somatic mutations in MECP2, met the diagnostic criteria for typical RTT, and displayed an overall phenotype identical to females with RTT. Additionally, we identified two XY boys with germline MECP2 mutations who on initial evaluation met criteria for atypical RTT.
However, when we carefully reviewed the historical and clinical information on all the cases we determined that an additional 12 subjects met the diagnostic criteria for atypical RTT. Critically, all had a history of regression.
Although they met criteria for atypical RTT, they all had clinical features that are distinctive from girls and women with RTT. Notably, they displayed less frequent and more variable hand stereotypies, less frequent periodic breathing, and absence of characteristic eye pointing. As mentioned previously, the clinical course for these individuals appears more severe than observed in girls and women with RTT, with more impaired initial development, ventilatory requirement, and early death. We believe that these features make this clinical pattern distinctive enough to warrant assignment to a novel and distinctive diagnostic category, which we term "Male RTT encephalopathy". This diagnostic classification incorporates sufficient clinical features to assign a general diagnosis of RTT, but also acknowledges that the overall pattern and progression of disease is different from typical RTT seen in females with MECP2 mutations. We propose that the criteria for the diagnosis of male RTT encephalopathy be (1) completely meeting criteria for RTT, meaning having clearly identified pattern of regression, displaying at least two of the four main criteria, and at least five of eleven supportive criteria, (2) mutation in MECP2, (3) male sex. It is important to note that the mere presence of a MECP2 mutation in a male is not sufficient to make the diagnosis of male RTT encephalopathy, as 14/28 males in this study did not meet criteria for RTT and are not considered to have male RTT encephalopathy. In these cases, the diagnosis of neonatal encephalopathy/progressive encephalopathy/cognitive impairment with a MECP2 mutation should continue to be applied.
| CONCLUSION
In males, mutations in MECP2 are compatible with life and result in a spectrum of neurodevelopmental features. Detailed characterization of these males contributes to the delineation of a new diagnostic entity in a subset: male RTT encephalopathy. The latter includes the key RTT diagnostic feature, developmental regression, but also a more severe clinical course than typical RTT in females. Increased awareness of the clinical spectrum seen in males with MECP2 mutations and systematic application of whole exome or genome sequencing may aid in increased identification of other males and improve our understanding of their involvement in this condition.
